Daily Fishing and Outdoor Report
Forced to hire domestic labor, Piss-Off Airlines first spotted trouble in their parcel-delivery division ... something they attributed to a faulty conveyor belt system.
The prefect approach by any sane editor ...
Tuesday, November 20, 2018: It remains a gorgeous ocean out there. OK, so maybe it’s overcast and was spitty earlier but the ocean water is immaculate – a fine light green/blue tint. Wind-wise, I can’t imagine any boat bassers staying in port today, short of the previously mentioned need to get in some worktime prior to the long holiday weekend. That said, I have also detected a significant downturn in what had been banner boat bassing. Not sure if this could be a big seasonal turn-off or simply a pause before further-north trophy stripers move on-scene.
Like this. Just this a.m.
Theoretically, the schoolie showing should soon be astronomical. Once again, the boat people will have a monumental advantage over surfcasters and bank anglers. Here’s hoping a late-day near-beach schoolie charge kicks in … starting today. As hard as I try, I can’t help being optimistic despite this continuing to be the worst fall surf run of stripers possibly in modern history. Nonstop schoolies would ease the surfside stripering pain.
I’ve already gotten two emails asking for gift ideas for the angler/outdoorsman. Yes, for your sakes I’ve mentioned Van Staals and a new loaded Chevy Silverado 4X. I’m working on a more practical list, though my quirky tastes in gadgets is far from everyone’s cup of gift tea.
By the by, I got my four-pack of Trac-Grabber x4 -The Get Unstuck Traction Solution for Trucks and SUVs. They’re quite decently made. I simply refuse to purposely sink my truck to see if they work. The video evidence of their effectiveness is mighty impressive, though. I placed one on a tire and it was quite easy to apply, though it sure seems like too little to free a badly bogged down truck. Still, the videos show absolutely chassis-stuck trucks busting out of entrapment with Trac-Grabbers.
My remote tire-pressure gauge gadgets are great … but not for me, per se. They go on each tire valve, then remotely communicate psi info through a dashboard-mounted reader. I had hoped to monitor my purposely low 25 psi buggying tires to make sure I wasn’t leaking air, which happens all too often when you frequently air down and air up for beach going. Upon testing, the reader perfectly displayed the tire pressure in all four tires, separately. The problem for buggyists is the fact each tire gauge leads to a warning sound if tire pressure is low – which it always is on a beach-ready buggy. It’s not a total loss, though. I can still monitor my tires, once filled to proper road psi levels, to make sure buggying didn’t throw a sand grain into a valve cap, easily leading to a slow leak capable of fully flattening a tire, especially overnight. Waking to a flat tire on a soaking or frigid morning is an all-time a.m. pisser for me. Once pancaked, a tire can’t be refilled unless the truck is jacked up.
One of my better buggying-related buys was a rugged Porter-Cable 6 Gal. 150 PSI Portable Electric Pancake Air Compressor. This is an entry-level compressor but quite adequate for nonprofessional applications. I keep it at the ready for faster post-buggying tire refills. I also call on it to sandblast the likes of iron Colonial-era metal-detecting finds. Pure iron (Batsto-like) cleans amazingly well, though such cleaning should only be done on certain artifacts, most need to be left totally untouched to maintain historic accuracy. Then there’s my pulling out the compressor to instantly age/distress wood and driftwood for artwork, using a garnet grit fed into a tightly nozzled sand gun. Googles a must.
Far and away my most used gadget has been the NOCO Genius Boost Plus GB40 1000 Amp 12V UltraSafe Lithium Jump Starter. You are crazy not to have one of these – charged up and at the ready. I have used mine maybe a dozen times, helping dead-battery folks – who look at the small contraption with doubt that it can instantly start their vehicle. Bam! Engine starts right up. I had to self-use mine last week when I left too many things in my “lighter” sockets. There are many of these now, some with USB ports and such. I fully back the Genius Boost Plus as tried-and-proven.
WELCOME LENAPE: Just a quick and highly-belated welcome officially home to the state’s 3,000-member Nanticoke Lenni-Lenape Tribal Nation.
Trenton has just announced, via Attorney General Gurbir S. Grewal, that a legal settlement has been worked out whereby New Jersey has legally and officially recognized the American Indian Tribe … since 1982. Huh?
No, that isn’t me writing in an unclear manner. The state has essentially legally backtracked to officially accept the tribe in an after-the-fact manner, which will allow it to be historically recognized, garnering the Tribe a total of $2.4 million under a settlement agreement. The State has also agreed to formally notify all relevant state and federal agencies of the Tribe’s official recognition status.
In former legal language out of Trenton, there was due confusion over the Tribe even being here. That reared up within the U.S. General Accounting Office, which had been advised that the Garden State recognized no native American tribes. For the members of that historic tribe still living here, that offered an ax to grind – seeing they were here long before Trenton was even named same.
The formal recognition qualifies the Tribe for federal and state benefits provided by the federal Indian Arts and Crafts Act of 1990. Not for nothing, but you’d think the namers of Congressional acts could have come up with something more dignified than the “Indian Arts and Crafts Act of 1990.”
“Tribal rights are important rights, and through this settlement we’ve been able to affirm the status of the Nanticoke Lenni-Lenape Nation as an American Indian Tribe formally recognized by the State,” said Attorney General Grewal. “As a result of this settlement, there is no more ambiguity regarding the Tribe’s official status, and the Tribe’s forward progress cannot be impeded by any State-related recognition issues. I’m heartened that, through good faith negotiation, we’ve been able to resolve this matter fairly and bring an end to years of legal dispute.”Oh, it should be added that this official State recognition does not provide the Tribe with federal casino gaming rights. To its credit, the Nanticoke Lenni-Lenape Tribal Nation declaimed any interest in casino gaming rights.
Crazy, crazy fishing....Stopped on a huge pile and it was game on. We were limited out in about 15 minutes. One long drift saw 30-40 Striped Bass PER PERSON!!! We released over 50 keeper size Bass, and 150 shorts by 9AM!!! Couple of Blues, and Boston Macks mixed in...
Looks like the Bass should stick around through at least next week. ...
Copyright © 2018 Agence France-Presse
by Laure Fillon
November 20, 2018
Dozens of nations on Monday failed to agree on measures to preserve one of the planet's most valuable fish: the bigeye tuna, backbone of a billion-dollar business that is severely overfished.
Some 50 countries as well as European Union member states wrapped up a meeting of the International Commission for the Conservation of Atlantic Tunas (IC...in the Croatian seaside city of Dubrovnik without reaching a consensus on quotas.
"It's a setback and it's bad news," said Javier Garat Perez, secretary general of the Spanish fishing confederation Cepesca.
Scientists shocked many in the industry last month when they warned that unless catch levels are sharply reduced, stocks of the fatty, fast-swimming predator could crash within a decade or two.
They warned that populations had fallen to less than 20 percent of historic levels.
Less iconic than Atlantic bluefin but more valuable as an industry, bigeye (Thunnus obesus) -- one of several so-called tropical tunas -- is prized for sashimi in Japan and canned for supermarket sales worldwide.
Three years ago, ICCAT introduced a 65,000-tonne catch limit for the seven largest fishers of bigeye, and a moratorium in certain areas of ocean.
But other countries are not bound by the quotas, and bigeye hauls last year topped 80,000 tonnes -- far too high to begin replenishing stocks.
The Dubrovnik meeting saw calls to bring countries fishing more than 1,575 tonnes such as Brazil, Senegal, Guatemala and Cape Verde under quotas but these were blocked due to commercial interests, many delegates said.
"The industry wants to make money and in the quickest way it can," said Siphokazi Ndudane, who headed the South African delegation at the talks.
The current quota of 65,000 tonnes was extended for a year as well as a partial moratorium on Fish Aggregating Devices or FADs: buoys or floats tethered to the ocean floor with concrete blocks which attract certain types of fish.
The last proposal at the conference was made by South Africa which suggested a quota of 62,500 tonnes from 2019 to 2021.
Some disappointed delegates sounded the alarm.
"If we don't reach consensus next year, it's catastrophe," said Yvan Riva, president of the French fishing organisation Orthongel.
The various players also traded blame.
Garat Perez pointed to Asian countries saying they "tried to avoid any measure that could affect their fleet of longliners," adding that "Europeans were prepared to make sacrifices."
But one member of a coastal African nation said it was a "lack of will" on the part of the big fishing nations.
Some experts have calculated that cutting the total catch to 50,000 tonnes per year would give bigeye a 70 percent probability of recovery by 2028.
Some delegates said the ICCAT had not taken in the lessons from the bluefin tuna.
In 2007 when one species of bluefin (Thunnus thynnus) was put on the UN list of threatened species, the ICCAT was forced to adopt drastic protective measures in the Atlantic and Mediterranean and stocks began to recover.
In Dubrovnik, after lengthy negotiations, the ICCAT put in place its 2019 management plan including relaxed fishing periods and for developing countries, the opportunity to set up bluefin tuna fattening farms.
"Bottom line, there are simply too many boats in the water chasing too few fish," said Paulus Tak, a senior officer for the Pew Charitable Trusts, and an official observer at the ICCAT meeting, about the bigeye tuna situation.
Photo Credit: ICCAT
November 19, 2018
This year you’re going to want to ring in the New Year with “marine munchies.” Whole Foods Market released their “most anticipated and innovative food trends for 2019,” and based on their fourth annual trends predictions, 2019 will be the year of seaweed snacks.
According to Whole Foods’ experts, seaweed snacks “rose to popularity” a few years ago. However, they expect “even more ocean influence in the grocery aisles in the year to come.” Shoppers can expect to see things like seaweed butter and kelp noodles.
“Puffed snacks made from water lily seeds, plant-based tuna alternatives with algae ingredients, crispy snackable salmon skins with omega-3s and kelp jerkies are just a few testing the waters.”
Nation’s Restaurant News reported earlier this year that U.S. consumption of seafood is growing at about 7% a year. “Sea vegetables in the higher level of dining have been growing rapidly over the past 10 years – and over the past three incredibly fast,” James E. Griffin, associate professor at Johnson & Wales University, told the outlet.
While you can find seaweed in appetizers and desserts at some restaurants, more unique items will be hitting the grocery store shelves. Just this past February Alaska’s Barnacle Foods’ “kelp salsa” won the Alaska Symphony of Seafood Juneau People’s Choice award. Earlier this fall Alaska’s Kodiak Island Brewing Co. created the state’s first kelp-b....
Other trends on Whole Foods’ 2019 list include: Pacific Rim flavors, shelf-stable probiotics, phat fats, next level hemp, faux meat snacks, eco-conscious packaging, trailblazing frozen treats, upgraded snack time, and “purchases that empower.”
Copyright © 2018 Forbes Media LLC
by Matthew Herper
November 20, 2018
Vascepa is not just any fish oil, and is different from over-the-counter supplements.
Cardiologists are still grappling with clinical trial results released last week that showed that Vascepa, a fish-oil-derived drug, reduced heart attacks, strokes, and deaths from cardiovascular disease by 25% in patients who had elevated triglycerides, or particles of fat in the blood. Views range from “healthy skepticism” to a hope that the study could rank among the most important ever in cardiology.
The apparently astounding benefit was paired with a number of caveats that some doctors worry could have inflated Vascepa’s apparent benefit, including a mystery as to exactly how the medicine works, a placebo that could have hurt patients, and previous studies of lower doses of similar fish oil drugs that were resoundingly negative. (Vascepa is a purified form of eicosapentaenoic acid, or EPA, a component of fish oil.) Some top researchers have visibly struggled with the results. The drama has been accentuated because Amarin Pharmaceuticals, Vascepa’s maker, is a small company with a devoted following of vocal individual investors.
How much can a doctor’s opinion shift on these data? When the headline results were released by press release in September, Sekar Kathiresan, director of the Cardiovascular Disease Initiative at the Broad Institute, at first reacted to the news by saying "Wow!" When he saw the results as published in the New England Journal of Medicine, he worried about exactly how the drug was working, and said he was "probably a little too enthusiastic with my initial comment." But he now thinks his initial reaction was probably right, and that the Vascepa results constitute a major advance.
James Stein, Robert Turell Professor of Cardiovascular Research at the University of Wisconsin, is a skeptic, believing that the placebo group in the study probably raised cardiovascular risk, making Vascepa look better than it was. But he’s still planning to try Vascepa in some patients. “I don’t know how much to discount it’s effectiveness,” Stein says. Even if he assumes that half of the effect was from the placebo, the benefit is still better than moving from a low dose of atorvastatin, the popular cholesterol drug, to a higher one. He doesn’t plan to prescribe the drug (or other fish oils) to people on anti-clotting drugs like Plavix, though, because it may increase the risk of bleeding. “That’s where I am today,” he says.
In an editorial that accompanies the study’s publication in the print edition of the New England Journal of Medicine, John J.P. Kastelein and Erik S.G. Stroes of the Academic Medical Center, University of Amsterdam, Amsterdam write: “We welcome these results with surprise, speculation, and hope.” They express concern that the data aren’t explained by Vascepa’s expected mechanism of lowering triglycerides, that the result conflicts with previous trials of fish oils, and that the placebo group may have had an effect. Kastelein is among the researchers conducting a 13,000 patient study of Epanova, another fish-oil-derived drug manufactured by AstraZeneca,
Should doctors use Vascepa? “They should use it,” Kastelein wrote via email. “The only thing we are waiting for is to learn whether Vascepa is unique or other fish-oil preparations or other doses of EPA have less, similar or better efficacy.”
Not everyone is so sure. “I have what I would say is some healthy skepticism about the results,” says Eric Topol, the Gary & Mary West Endowed Chair of Innovative Medicine, Scripps Research. The main reason, he says, is that the study doesn’t fit with the many other studies of lower doses of fish oil preparations that have shown no benefit. Another worry, he says, is that triglyceride-lowering does not seem to explain the cardiovascular benefit that was seen. “That is distressing,” he says, “because we have no idea what the mechanism is. The assertion that it’s just because of high EPA dose or pure EPA, that’s all speculation.”
Topol also has concerns that the placebo may have raised cholesterol and c-reactive protein. “They happened to have a placebo that’s not inert,” he says. That won’t explain the results he says, but it’s also not helping to sort things out. He says he’s not comforted by an analysis showing that the results hold up when researchers analyzed them with just the patients in the placebo group whose low-density lipoprotein (LDL, the "bad cholesterol") went up, or just those in whom LDL stayed flat. “That’s just one way of looking at it,” he says. “It probably should be looked at in multiple ways." Still, he says: "At the end of the day, I don’t think that the main explanation is that the placebo is the problem. I doubt it was the singular problem. It was contributing.”
“There’s too many warts here to make [it seem] that this is pure triumph,” Topol says. “There’s some things that just don’t compute.”
Other top cardiology researchers had far more positive views. Jane Armitage, an epidemiologist at the Nuffield Department of Population Health at Oxford University, writes via email that it is “very unlikely that the small dose of the placebo oil is likely to have caused any problem, although it is slightly odd that they chose a mineral oil rather than a vegetable oil.” She argues the results are “believable in light of the prior evidence.”
Unlike other experts, who largely believe that Vascepa’s effects must go beyond lowering triglycerides to preventing cardiovascular disease in other ways, perhaps by reducing the risk of sudden cardiac death or clots, Armitage believes that the 44 milligram per deciliter drop in triglycerides seen in the study could explain the benefit. She points toa 2011 analysis of multiple studies of fibrates, a different type of triglyceride-lowering drug, which showed a similar benefit in patients with high triglycerides. Other fish oil trials probably failed because they used much lower doses. “It seems that high doses of fish oils are needed to gain benefit at least in this high triglyceride population,” Armitage writes.
Even most proponents of the argument that the placebo in the study was harmful doubt that it increased the rate of events more than 5%; it’s the lack of a clear understanding of how the drug is working that bothers them most. But Rory Collins, the head of the Nuffield department at Oxford , argued in an email that other factors could explain the increase in cholesterol seen in the placebo group. One factor is that low cholesterol was required for patients entering the study. That could have meant that researchers were picking people at what was a low cholesterol level for them, and the levels simply returned to normal. (This is called regression to the mean.) It also could be the result, he says, of statistical quirks because the tests weren’t collected in random order — and effect that researchers could test for by going back to banked blood samples.
“An effect of the mineral oil remains a possibility, but my guess would be that it is largely if not wholly an effect of the high-dose EPA through mechanisms beyond merely lowering [triglycerides],” Collins writes. He poses a provocative question: what if the Vascepa study, called REDUCE-IT, is to EPA what a 1995 study called 4S was to cholesterol-lowering drugs called statins?The 4S study, also known as the Scandinavian Simvastatin Survival Study, was funded by Merck and released in 1994. It was the first study to show that a cholesterol-lowering statin drug prevented heart attacks and, indeed, saved lives in patients who already had heart disease. It started years of debate, and the drug used in the study, Zocor, was surpassed by rival medicines made by other companies. But the statins become one of the most popular classes of drugs the world has ever seen, generating hundreds of billions of dollars in sales and saving countless lives.
It’s a question, not an answer. In recent years, new cardiovascular drugs have been commercial flops even when they seemed like scientific successes. But it is a tantalizing possibility.